{"id":"intramuscular-haloperidol","safety":{"commonSideEffects":[{"rate":null,"effect":"Extrapyramidal symptoms (dystonia, akathisia, parkinsonism)"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Orthostatic hypotension"},{"rate":null,"effect":"Tardive dyskinesia (with chronic use)"},{"rate":null,"effect":"Neuroleptic malignant syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Haloperidol antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, which reduces positive symptoms of psychosis such as hallucinations and delusions. The intramuscular formulation provides rapid onset of action and is used for acute agitation or when oral administration is not feasible. It also has some activity at other dopamine receptors and possesses anticholinergic properties.","oneSentence":"Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms and agitation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:46.837Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation and psychosis"},{"name":"Schizophrenia"},{"name":"Bipolar disorder with acute mania"}]},"trialDetails":[{"nctId":"NCT06395428","phase":"PHASE4","title":"Haloperidol for Pain Control in Patients With Acute Musculoskeletal Back Pain in the Emergency Department","status":"RECRUITING","sponsor":"Western Michigan University School of Medicine","startDate":"2024-07-09","conditions":"Back Pain, Chronic Pain","enrollment":75},{"nctId":"NCT05995457","phase":"NA","title":"The IM-ZBULLE Study : \" Z-track \" and \" Airlock \" Techniques During Intramuscular Injection of Haloperidol Decanoate","status":"UNKNOWN","sponsor":"Centre Hospitalier St Anne","startDate":"2023-09-01","conditions":"Schizophrenia; Psychosis","enrollment":84},{"nctId":"NCT05803642","phase":"PHASE3","title":"A Study of Olanzapine in Patients With Acute Agitation","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-03-28","conditions":"Acute Agitation","enrollment":318},{"nctId":"NCT02380118","phase":"PHASE4","title":"IM Olanzapine Versus Haloperidol or Midazolam","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Acute Agitation, Behavioural Emergency","enrollment":167},{"nctId":"NCT00723606","phase":"PHASE3","title":"A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":376},{"nctId":"NCT03110900","phase":"PHASE4","title":"Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2017-09-30","conditions":"Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use","enrollment":2},{"nctId":"NCT03211897","phase":"","title":"Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation","status":"COMPLETED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2017-06-15","conditions":"Agitation,Psychomotor","enrollment":737},{"nctId":"NCT00786318","phase":"PHASE4","title":"Ziprasidone vs Standard Therapy for Agitated Patients in the ED","status":"WITHDRAWN","sponsor":"George Washington University","startDate":"2008-09","conditions":"Psychosis, Agitation, Delirium","enrollment":""},{"nctId":"NCT02103881","phase":"PHASE4","title":"Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital","status":"WITHDRAWN","sponsor":"Hennepin Healthcare Research Institute","startDate":"2014-04","conditions":"Agitation","enrollment":""},{"nctId":"NCT01136772","phase":"PHASE4","title":"A Comparison of Long-acting Injectable Medications for Schizophrenia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2011-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":311},{"nctId":"NCT00797277","phase":"PHASE3","title":"Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder, Agitation","enrollment":67},{"nctId":"NCT00189995","phase":"PHASE3","title":"Clozapine IM and Aggression in Schizophrenic Patients","status":"WITHDRAWN","sponsor":"Beersheva Mental Health Center","startDate":"","conditions":"Schizophrenia","enrollment":""},{"nctId":"NCT01750541","phase":"PHASE3","title":"Haloperidol vs. Valproate in Agitation","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2012-12","conditions":"Psychomotor Agitation","enrollment":56},{"nctId":"NCT01485692","phase":"NA","title":"Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2009-02","conditions":"Psychomotor Agitation","enrollment":120},{"nctId":"NCT00866645","phase":"PHASE2, PHASE3","title":"A Study To Evaluate The Efficacy And Safety Of Intramuscular Levosulpiride In Patients With Agitation Of Schizophrenia","status":"COMPLETED","sponsor":"Shanghai Mental Health Center","startDate":"2009-02","conditions":"Agitation","enrollment":240},{"nctId":"NCT00859872","phase":"PHASE4","title":"Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia","status":"COMPLETED","sponsor":"Central South University","startDate":"2008-08","conditions":"Schizophrenia","enrollment":198},{"nctId":"NCT00947375","phase":"PHASE4","title":"Lamictal TM, Haloperidol Decanoate in Schizophrenia","status":"TERMINATED","sponsor":"Central Mental Clinic for Outpatients of Baku City","startDate":"2005-01","conditions":"Schizophrenia","enrollment":335},{"nctId":"NCT00485901","phase":"PHASE3","title":"Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-07","conditions":"Schizophrenia","enrollment":50},{"nctId":"NCT00455234","phase":"PHASE3","title":"Rapid Tranquillization Trial: TREC-India II","status":"COMPLETED","sponsor":"Christian Medical College, Vellore, India","startDate":"2005-09","conditions":"Psychotic Disorders, Aggression","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":98,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Intramuscular Haloperidol parenteral solution","Haldol"],"phase":"phase_3","status":"active","brandName":"Intramuscular Haloperidol","genericName":"Intramuscular Haloperidol","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Haloperidol is a typical antipsychotic that blocks dopamine D2 receptors in the brain to reduce psychotic symptoms and agitation. Used for Acute agitation and psychosis, Schizophrenia, Bipolar disorder with acute mania.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}